{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:05:37Z","timestamp":1777421137148,"version":"3.51.4"},"reference-count":25,"publisher":"SAGE Publications","issue":"11","license":[{"start":{"date-parts":[[2021,2,20]],"date-time":"2021-02-20T00:00:00Z","timestamp":1613779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      Oseltamivir is frequently administered to critically ill patients with presumed influenza. It may modulate Na\n                      <jats:sup>+<\/jats:sup>\n                      , K\n                      <jats:sup>+<\/jats:sup>\n                      , and Ca\n                      <jats:sup>2+<\/jats:sup>\n                      channels to produce bradycardia.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To evaluate the association between oseltamivir and bradycardia in critically ill patients and assess parameters associated with bradycardia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This was a retrospective audit of 203 critically ill adults with presumed influenza receiving at least 2 doses of oseltamivir. The primary outcome was the occurrence of bradycardia, defined as a heart rate (HR) \u226459 beats per minute (BPM) while receiving oseltamivir or a decrease of \u226520 BPM compared with the lowest HR before initiating oseltamivir.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 88 (43.4%) patients manifested bradycardia, 59 with HR \u226459 BPM, 19 with HR decrease of \u226520 BPM, and 10 with both. The time from first dose to bradycardia was 51.4 \u00b1 43 hours. In all, 48 (54.6%) patients received therapies for bradycardia, including increased inotropic\/vasopressor dose, electrolyte replacement, electrocardiogram, discontinuation of other medications, cardiology consult, discontinuation of oseltamivir, and pacer placement. There were no significant differences between groups with bradycardia versus without in terms of demographics, laboratory values, hospital characteristics, or oseltamivir dosing. Multivariate logistic regression showed that bradycardia was associated with baseline HR, age, past medical history of neurological issues, and positive influenza status. Between hours 6 through 126, significant differences existed between groups in actual and lowest HR.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion and Relevance:<\/jats:title>\n                    <jats:p>Oseltamivir was associated with clinically relevant bradycardia in critically ill patients. Clinicians should closely monitor HR in critically ill patients receiving oseltamivir.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1060028020988919","type":"journal-article","created":{"date-parts":[[2021,2,20]],"date-time":"2021-02-20T05:17:02Z","timestamp":1613798222000},"page":"1318-1325","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Oseltamivir-Associated Bradycardia in Critically Ill Patients"],"prefix":"10.1177","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3569-5506","authenticated-orcid":false,"given":"Robert","family":"MacLaren","sequence":"first","affiliation":[{"name":"University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janelle","family":"Francisco","sequence":"additional","affiliation":[{"name":"Schaffner Pharmacy, Sedro Woolley, WA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan","family":"Fetters","sequence":"additional","affiliation":[{"name":"Centura St Anthony Hospital, Lakewood, CO, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Brady","sequence":"additional","affiliation":[{"name":"University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Crystal","family":"Kim","sequence":"additional","affiliation":[{"name":"University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cameron","family":"Welker","sequence":"additional","affiliation":[{"name":"University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2021,2,20]]},"reference":[{"key":"bibr1-1060028020988919","unstructured":"Centers for Disease Control and Prevention. Disease burden of influenza. Accessed October 1, 2020. https:\/\/www.cdc.gov\/flu\/about\/burden\/index.html"},{"key":"bibr2-1060028020988919","unstructured":"Tamiflu\u00ae. Package insert. Genentech; 2019. Accessed January 6, 2021. https:\/\/www.gene.com\/download\/pdf\/tamiflu_prescribing.pdf"},{"key":"bibr3-1060028020988919","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008965.pub4"},{"key":"bibr4-1060028020988919","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)62449-1"},{"key":"bibr5-1060028020988919","doi-asserted-by":"publisher","DOI":"10.1097\/MCP.0000000000000667"},{"key":"bibr6-1060028020988919","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy866"},{"key":"bibr7-1060028020988919","unstructured":"World Health Organization. Executive summary: The selection and use of essential medicines 2019. Report of the 22nd WHO Expert Committee on the selection and use of essential medicines. Accessed October 1, 2020. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/325773\/WHO-MVP-EMP-IAU-2019.05-eng.pdf?ua=1"},{"key":"bibr8-1060028020988919","doi-asserted-by":"publisher","DOI":"10.1111\/ane.12629"},{"key":"bibr9-1060028020988919","doi-asserted-by":"publisher","DOI":"10.1080\/23744235.2016"},{"key":"bibr10-1060028020988919","doi-asserted-by":"publisher","DOI":"10.1016\/j.jphs.2016.04.018"},{"key":"bibr11-1060028020988919","doi-asserted-by":"publisher","DOI":"10.2131\/jts.43.507"},{"key":"bibr12-1060028020988919","doi-asserted-by":"publisher","DOI":"10.1007\/s12012-013-9202-6"},{"key":"bibr13-1060028020988919","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.b13-00347"},{"key":"bibr14-1060028020988919","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2015.06.004"},{"key":"bibr15-1060028020988919","unstructured":"European Medicines Agency. Marketing Authorization Application, Table of Contents\u2013Volume 81. 1007\u2013Brewster M. Ro 64\u20130802\/002 (GS\u20134071) cardiovascular and respiratory evaluation in the anaesthetized dog following intravenous administrations (DHB08601).RR W\u2013142974. 1999 (disclosed document from EMA). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/021246Orig1s045_021087Orig1s062PharmR.pdf"},{"key":"bibr16-1060028020988919","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-017-1415-y"},{"key":"bibr17-1060028020988919","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-017-1415-y"},{"key":"bibr18-1060028020988919","doi-asserted-by":"publisher","DOI":"10.1016\/j.eimc.2019.05.010"},{"key":"bibr19-1060028020988919","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2010.03.009"},{"key":"bibr20-1060028020988919","first-page":"155","volume":"7","author":"Chahine K","year":"2019","journal-title":"Pharm Pharmacol Int J"},{"key":"bibr21-1060028020988919","first-page":"33","volume":"5","author":"Dharmesh S","year":"2018","journal-title":"Int J Adv Case Rep"},{"key":"bibr22-1060028020988919","doi-asserted-by":"publisher","DOI":"10.18203\/2319-2003.ijbcp20185177"},{"key":"bibr23-1060028020988919","unstructured":"eHealthMe. Tamiflu: effectiveness, side effects, alternatives. Accessed October 1, 2020. https:\/\/www.ehealthme.com\/drug\/tamiflu"},{"key":"bibr24-1060028020988919","unstructured":"VigiAccess\u2122. Oseltamivir. Accessed October 1, 2020. http:\/\/vigiaccess.org"},{"key":"bibr25-1060028020988919","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1702090"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028020988919","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1060028020988919","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028020988919","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:16:07Z","timestamp":1777374967000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1060028020988919"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,20]]},"references-count":25,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["10.1177\/1060028020988919"],"URL":"https:\/\/doi.org\/10.1177\/1060028020988919","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,20]]}}}